Andrey B. Gryazov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Andrey B. Gryazov has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Oksana V. Zemskova
State Institution «Romodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine», Kyiv, Ukraine
8 shared publications - Oleksandr Yakovych Glavatskyi
Державна установа «Інститут нейрохірургії ім. акад. А. П. Ромоданова НАМН України», Україна, 04050, м. Київ, вул. П. Майбороди, 32
7 shared publications - Olga Yuriivna Chuvashova
State Institution «Romodanov Neurosurgery Institute National Academy of Medical Sciences of Ukraine», Kyiv, Ukraine
6 shared publications - Volodymyr A. Stuley
National Technical University of Ukraine «Igor Sikorsky Kyiv Polytechnic Institute», Institute for Applied Systems Analysis of the Ministry of Education and Science of Ukraine, Kyiv, Ukraine
6 shared publications - Iryna V. Kruchok
Department of Neuroradiology and Radioneurosurgery, Romodanov Neurosurgery Institute, Kyiv
5 shared publications - Viktor Petrovych Starenkiy
Grigoriev Institute for Medical Radiology and Oncology NAMSU,Radiation Oncology Department,Kharkiv,Ukraine
5 shared publications
Latest Publications
- Open Access
- 2 July 2024
- Published by Institute for Medical Radiology and Oncology of NAMS of Ukraine in Український радіологічний та онкологічний журнал
- Vol. 32 (2)
The analysis of quality of life of patients with glioblastoma after adjuvant radiation therapy
Background. Optimizing approaches to the treatment of patients with glioblastoma (GB) is an urgent task partly owing to the wider implementation of hypofractionated radiation therapy (HRT) regimens. At the same time, increasing survival without maintaining the patient’s quality of life (QoL) cannot be considered successful treatment. Purpose – to analyze QoL of patients with GB after adjuvant radiation treatment in the groups of standard and hypofractionated radiation regimens. Materials and methods. 159 patients with verified GB, who had undergone surgery in State Institution «Romodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine» over the period from 2014 to 2020, were divided into two groups according to the regimen of RT: SRT group (n = 49) – standard regimen (total dose 60.0 Gy in 30 fractions over 6 weeks); HRT group (n = 110) – hypofractionated regimen (total dose 52.5 Gy in 15 fractions over 3 weeks). The patients were surveyed about QoL three times during their follow-up (3, 6 and 12 months after RT) according to the Global Health Status Scale (GHSS), domains of insomnia and fatigue of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30 version 3.0). Statistical analysis was performed separately for each group (SRT and HRT; intragroup analysis), as well as between SRT and HRT groups as comparison of independent groups with a different number of follow-up examinations for each period of the follow-up (intergroup analysis). Results. The H0 hypothesis about the absence of statistically significant difference between the results of three subsequent surveys according to the GHSS, domains of insomnia and fatigue in both SRT (p = 0.00003; p = 0.00002; p = 0.00002, respectively) and HRT (p = 0.00000; p = 0.00001; p = 0.00001, respectively) groups in the intragroup analysis according to the Friedman test was rejected. The pairwise comparison of the results of the second and the first survey (6 vs. 3 months) according to the Wilcoxon test showed a statistically significant decrease in QoL in the domain of insomnia (р = 0.000733) in SRT group and in the domain of fatigue (р = 0.016813) in HRT group. When comparing the results of the third and the second survey (12 vs. 6 months), the H0 hypothesis for all the studied parameters of QoL (GHS, insomnia, and fatigue) was rejected in both SRT and HRT groups (p ≤ 0.017 with the Bonferroni correction). When comparing the results of the third and the first survey (12 vs. 3 months), a statistically significant decrease in QoL in all studied parameters of QoL was observed: GHSS (р = 0.000078); fatigue (р = 0.000294); insomnia (р = 0.000318). The comparison of the results of these surveys in SRT group showed a statistically significant decrease of QoL in GHSS (р = 0.004650) and fatigue (p = 0.017938), with the level of statistical significance getting closer to the set critical value considering the Bonferroni correction. The intergroup analysis according to the Mann-Whitney U test showed a statistically significant advantage of HRT over SRT in all studied parameters of QoL in three subsequent surveys (p < 0.05). The ρ-test confirmed these data: HRT group patients had better parameters of QoL than SRT group patients over the whole period of the follow-up. Conclusions. The analysis of QoL according to the results of three subsequent surveys 3, 6, and 12 months after RT according to the GHSS, domains of insomnia and fatigue of the EORTC QLQ-C30 demonstrated a decrease in QoL of patients in both SRT and HRT groups. At the same time, a statistically significant advantage of HRT group over SRT group in all studied parameters of SRT was observed when the results of three subsequent surveys were compared. The proposed regimen of HRT for patients with primarily diagnosed GB may be considered an acceptable alternative to SRT in view of impact on QoL.
- 2 July 2024
- Published by Institute for Medical Radiology and Oncology of NAMS of Ukraine in Український радіологічний та онкологічний журнал
- Vol. 32 (2)
Open AccessThe analysis of quality of life of patients with glioblastoma after adjuvant radiation therapy
Background. Optimizing approaches to the treatment of patients with glioblastoma (GB) is an urgent task partly owing to the wider implementation of hypofractionated radiation therapy (HRT) regimens. At the same time, increasing survival without maintaining the patient’s quality of life (QoL) cannot be considered successful treatment. Purpose – to analyze QoL of patients with GB after adjuvant radiation treatment in the groups of standard and hypofractionated radiation regimens. Materials and methods. 159 patients with verified GB, who had undergone surgery in State Institution «Romodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine» over the period from 2014 to 2020, were divided into two groups according to the regimen of RT: SRT group (n = 49) – standard regimen (total dose 60.0 Gy in 30 fractions over 6 weeks); HRT group (n = 110) – hypofractionated regimen (total dose 52.5 Gy in 15 fractions over 3 weeks). The patients were surveyed about QoL three times during their follow-up (3, 6 and 12 months after RT) according to the Global Health Status Scale (GHSS), domains of insomnia and fatigue of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30 version 3.0). Statistical analysis was performed separately for each group (SRT and HRT; intragroup analysis), as well as between SRT and HRT groups as comparison of independent groups with a different number of follow-up examinations for each period of the follow-up (intergroup analysis). Results. The H0 hypothesis about the absence of statistically significant difference between the results of three subsequent surveys according to the GHSS, domains of insomnia and fatigue in both SRT (p = 0.00003; p = 0.00002; p = 0.00002, respectively) and HRT (p = 0.00000; p = 0.00001; p = 0.00001, respectively) groups in the intragroup analysis according to the Friedman test was rejected. The pairwise comparison of the results of the second and the first survey (6 vs. 3 months) according to the Wilcoxon test showed a statistically significant decrease in QoL in the domain of insomnia (р = 0.000733) in SRT group and in the domain of fatigue (р = 0.016813) in HRT group. When comparing the results of the third and the second survey (12 vs. 6 months), the H0 hypothesis for all the studied parameters of QoL (GHS, insomnia, and fatigue) was rejected in both SRT and HRT groups (p ≤ 0.017 with the Bonferroni correction). When comparing the results of the third and the first survey (12 vs. 3 months), a statistically significant decrease in QoL in all studied parameters of QoL was observed: GHSS (р = 0.000078); fatigue (р = 0.000294); insomnia (р = 0.000318). The comparison of the results of these surveys in SRT group showed a statistically significant decrease of QoL in GHSS (р = 0.004650) and fatigue (p = 0.017938), with the level of statistical significance getting closer to the set critical value considering the Bonferroni correction. The intergroup analysis according to the Mann-Whitney U test showed a statistically significant advantage of HRT over SRT in all studied parameters of QoL in three subsequent surveys (p < 0.05). The ρ-test confirmed these data: HRT group patients had better parameters of QoL than SRT group patients over the whole period of the follow-up. Conclusions. The analysis of QoL according to the results of three subsequent surveys 3, 6, and 12 months after RT according to the GHSS, domains of insomnia and fatigue of the EORTC QLQ-C30 demonstrated a decrease in QoL of patients in both SRT and HRT groups. At the same time, a statistically significant advantage of HRT group over SRT group in all studied parameters of SRT was observed when the results of three subsequent surveys were compared. The proposed regimen of HRT for patients with primarily diagnosed GB may be considered an acceptable alternative to SRT in view of impact on QoL.
- Open Access
- 22 March 2024
- Published by Institute for Medical Radiology and Oncology of NAMS of Ukraine in Український радіологічний та онкологічний журнал
- Vol. 32 (1) , 91-104
Glioblastoma: quality of life as a key element in evaluation of radiation treatment effectiveness
Background. Along with the traditional assessment of oncological outcomes with a focus on survival, information about the patient’s quality of life (QOL) plays a key role in evaluating the effectiveness of treatment. The QOL assessment reflecting a person’s subjective perception of their situation in the disease context is now considered a tool for changing the current paradigm of therapeutic effectiveness, including that in neuro-oncology. Modern high-tech radiation therapy offers wide possibilities for modifying radiation regimens, in particularly, by means of hypofractionation. Given the considerable clinical benefits of the latter, there is a growing interest in studies that include QOL assessment along with conventional biomedical outcomes, particularly in patients with glioblastoma. Purpose. This analytical review focuses on the clinical aspects of QOL assessment in the context of radiation treatment of glioblastoma patients, beyond the discussion of oncological outcomes. Materials and methods. References were analyzed using English-language biomedical databases (MEDLINE (Pubmed), EMBASE (Ovid), Web of Science (Web of Knowledge) using the following Keywords: «Quality of life», «Health-related quality of life», «Radiation Therapy», «Hypofractionated radiotherapy», «Hypofractionated irradiation», «CNS tumors», «Brain tumors», «Glioblastoma». When analyzing all sources, backlinks were made to the original sources to identify the additional relevant studies. The last date of the search was February 01, 2024. Results. Nowadays, QOL assessment is broadly integrated into the neuro-oncology practice. This analysis is used for the comprehensive treatment outcome assessment in various clinical scenarios, including modification of radiation therapy regimens. The results of cancer treatment are not considered satisfactory if the survival is not associated with the maintenance of QOL. The main tool for QOL assessment is the EORTC QLQ-C30 questionnaire; for patients with brain tumors, there is an additional specific module BN-20. QOL analysis demonstrates the benefits of hypofractionated radiation therapy for glioblastoma patients, as a reduced radiation course has a favorable impact on QOL, without significant difference in toxicity and expected survival compared to standard regimens. The QOL study proves the positive effect of combining adjuvant radiation therapy and neurorehabilitation for glioblastoma patients using virtual reality technology. It has been established that QOL remains stable following re-irradiation of patients with recurrent gliomas. QOL analysis provides the opportunities to reveal the medical and social aspects of neuro-oncological diseases and demonstrates the burden of the disease not only for the person directly affected by glioblastoma, but also for those who care for the patient. The number of publications dedicated to the QOL assessment in proton radiation therapy is growing. Conclusion. If there is no significant difference between the toxicity of treatments (including radiation) and expected survival, QOL can serve as a criterion for an optimal therapy selection. QOL analysis is used for the comprehensive treatment outcome assessment in various clinical scenarios, including modification of radiation therapy regimens (e.g., hypofractionation). QOL analysis is complex and requires unification. Acquiring the methodology of QOL assessment is a necessary requirement for researchers involved in modern neuro-oncology studies. Актуальність. Поряд з традиційною оцінкою онкологічних результатів з фокусом на виживаності, інформація про якість життя (ЯЖ) пацієнта відіграє ключову роль у визначенні успішності лікування. Оцінка ЯЖ, що є відображенням суб’єктивного сприйняття людиною свого становища в контексті певного захворювання, розглядається сьогодні як інструмент зміни сучасної парадигми терапевтичної ефективності, зокрема, в нейроонкології. Сучасна високотехнологічна променева терапія має широкі можливості щодо модифікації режимів опромінення за рахунок гіпофракціонування. Враховуючи суттєві клінічні переваги останніх, зростає інтерес до досліджень, що включають оцінку ЯЖ поряд із загальноприйнятими біомедичними результатами, зокрема, у пацієнтів з гліобластомою. Мета роботи – аналітичний огляд, що сфокусований на клінічних аспектах оцінки ЯЖ у ході променевого лікування пацієнтів з гліобластомою, поза межами обговорення онкологічних результатів. Матеріали та методи. Літературні джерела проаналізовані за допомогою англомовних текстових баз біомедичних метаданих (MEDLINE (Pubmed), EMBASE (Ovid), Web of Science (Web of Knowledge) за пошуковими ключовими словами «Quality of life», «Health-related quality of life», «Radiation Therapy», «Hypofractionated radiotherapy», «Hypofractionated irradiation», «CNS tumors», «Brain tumors», «Glioblastoma». При аналізі всіх джерел були зроблені зворотні посилання на першоджерела для виявлення...
- 22 March 2024
- Published by Institute for Medical Radiology and Oncology of NAMS of Ukraine in Український радіологічний та онкологічний журнал
- Vol. 32 (1) , 91-104
Open AccessGlioblastoma: quality of life as a key element in evaluation of radiation treatment effectiveness
Background. Along with the traditional assessment of oncological outcomes with a focus on survival, information about the patient’s quality of life (QOL) plays a key role in evaluating the effectiveness of treatment. The QOL assessment reflecting a person’s subjective perception of their situation in the disease context is now considered a tool for changing the current paradigm of therapeutic effectiveness, including that in neuro-oncology. Modern high-tech radiation therapy offers wide possibilities for modifying radiation regimens, in particularly, by means of hypofractionation. Given the considerable clinical benefits of the latter, there is a growing interest in studies that include QOL assessment along with conventional biomedical outcomes, particularly in patients with glioblastoma. Purpose. This analytical review focuses on the clinical aspects of QOL assessment in the context of radiation treatment of glioblastoma patients, beyond the discussion of oncological outcomes. Materials and methods. References were analyzed using English-language biomedical databases (MEDLINE (Pubmed), EMBASE (Ovid), Web of Science (Web of Knowledge) using the following Keywords: «Quality of life», «Health-related quality of life», «Radiation Therapy», «Hypofractionated radiotherapy», «Hypofractionated irradiation», «CNS tumors», «Brain tumors», «Glioblastoma». When analyzing all sources, backlinks were made to the original sources to identify the additional relevant studies. The last date of the search was February 01, 2024. Results. Nowadays, QOL assessment is broadly integrated into the neuro-oncology practice. This analysis is used for the comprehensive treatment outcome assessment in various clinical scenarios, including modification of radiation therapy regimens. The results of cancer treatment are not considered satisfactory if the survival is not associated with the maintenance of QOL. The main tool for QOL assessment is the EORTC QLQ-C30 questionnaire; for patients with brain tumors, there is an additional specific module BN-20. QOL analysis demonstrates the benefits of hypofractionated radiation therapy for glioblastoma patients, as a reduced radiation course has a favorable impact on QOL, without significant difference in toxicity and expected survival compared to standard regimens. The QOL study proves the positive effect of combining adjuvant radiation therapy and neurorehabilitation for glioblastoma patients using virtual reality technology. It has been established that QOL remains stable following re-irradiation of patients with recurrent gliomas. QOL analysis provides the opportunities to reveal the medical and social aspects of neuro-oncological diseases and demonstrates the burden of the disease not only for the person directly affected by glioblastoma, but also for those who care for the patient. The number of publications dedicated to the QOL assessment in proton radiation therapy is growing. Conclusion. If there is no significant difference between the toxicity of treatments (including radiation) and expected survival, QOL can serve as a criterion for an optimal therapy selection. QOL analysis is used for the comprehensive treatment outcome assessment in various clinical scenarios, including modification of radiation therapy regimens (e.g., hypofractionation). QOL analysis is complex and requires unification. Acquiring the methodology of QOL assessment is a necessary requirement for researchers involved in modern neuro-oncology studies. Актуальність. Поряд з традиційною оцінкою онкологічних результатів з фокусом на виживаності, інформація про якість життя (ЯЖ) пацієнта відіграє ключову роль у визначенні успішності лікування. Оцінка ЯЖ, що є відображенням суб’єктивного сприйняття людиною свого становища в контексті певного захворювання, розглядається сьогодні як інструмент зміни сучасної парадигми терапевтичної ефективності, зокрема, в нейроонкології. Сучасна високотехнологічна променева терапія має широкі можливості щодо модифікації режимів опромінення за рахунок гіпофракціонування. Враховуючи суттєві клінічні переваги останніх, зростає інтерес до досліджень, що включають оцінку ЯЖ поряд із загальноприйнятими біомедичними результатами, зокрема, у пацієнтів з гліобластомою. Мета роботи – аналітичний огляд, що сфокусований на клінічних аспектах оцінки ЯЖ у ході променевого лікування пацієнтів з гліобластомою, поза межами обговорення онкологічних результатів. Матеріали та методи. Літературні джерела проаналізовані за допомогою англомовних текстових баз біомедичних метаданих (MEDLINE (Pubmed), EMBASE (Ovid), Web of Science (Web of Knowledge) за пошуковими ключовими словами «Quality of life», «Health-related quality of life», «Radiation Therapy», «Hypofractionated radiotherapy», «Hypofractionated irradiation», «CNS tumors», «Brain tumors», «Glioblastoma». При аналізі всіх джерел були зроблені зворотні посилання на першоджерела для виявлення...
- Open Access
- 29 December 2023
- Published by Institute for Medical Radiology and Oncology of NAMS of Ukraine in Український радіологічний та онкологічний журнал
- Vol. 31 (4) , 362-377
Factors affecting the survival of patients with glioblastoma treated with standard and hypofractionated radiation regimens
Background. Glioblastoma has the worst prognosis and is the most common primary tumor of the central nervous system (CNS) among adults. Since it is multimodal treatment that increases survival chances of patients with glioblastoma, the analysis of factors that affect survival is a necessary precondition for developing more effective therapeutic approaches for this cohort. Such analysis makes it possible to determine the subgroups of patients which demonstrate the biggest therapeutic benefit from certain types of multimodal treatment, thus leading to implementation of personalized neuro-oncological treatment. Purpose. To analyze factors affecting cancer-specific survival (CSS) of patients with glioblastoma in stratification of the cohort according to the regimen of adjuvant radiation therapy into groups of standard and hypofractionated treatment regimens. Materials and methods. The single-center non-randomized study is based on the analysis of the results of the cohort of 159 patients with primarily diagnosed glioblastoma that were treated over the period from 2014 to 2020 at the State Institution «Romodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine». According to the regimen of radiation therapy, the patients of the cohort (n=159) were stratified into two groups: standard regimen group – 49 (30.8%) patients (30 fractions, total radiation dose of 60.0 Gy) and hypofractionated regimen group – 110 (69.2%) patients (15 fractions, total radiation dose of 52.5 Gy). The survival of the patients was analyzed by the Kaplan–Meier method. The log-rank test was used for comparing Kaplan–Meier survival curves for different studied groups. For the purpose of studying impact of independent variables on the survival, we used regression analysis according to semiparametric proportional hazards model. Hazard ratio was calculated with 95% confidence intervals (CI). Results and discussion. The median CSS in the total cohort was 16.6 (95% CI 14.1–17.8 months) months in median follow-up time of 23.8 (95% CI 21.9–27.3) months. In standard regimen group, the median CSS was 15.7 (95% CI 14.1–17.8) months in median follow-up time of 24.4 (95% CI 23.1–25.3) months. In hypofractionated regimen group, the median CSS was 17.5 (95% CI 14.6–19.7) months in median follow-up time of 22.3 (95% CI 21.3 – 27.2) months. According to the logrank test (taking into consideration cautions about its use), no statistically significant difference in CSS of patients of both groups was determined р=0.07>0.05. For analysis of the impact of clinical factors (age, sex, radicality of the surgical treatment, chemotherapeutic treatment, functional status according to the Karnofsky scale) on the CSS of both groups, they were considered as the ones that may have different base hazard. Statistically significant impact of all studied covariates on the CSS was registered (p70 points, ceteris paribus. For male patients, the hazard of death is 1.7 times higher (р=0.016267; HR 1.7; 95% CI 1.1–2.5) than for female patients, ceteris paribus. Absence of chemotherapy in adjuvant treatment increases hazard of death by 2.37 times (HR 2.37; 95% CI 1.6–3.2), ceteris paribus. The hazard of death decreases, ceteris paribus, by 82% in chemotherapy with temozolomide and by 47% when the patient is younger than 60 years old (HR 0.53; 95% CI 0.4–0.8). Conclusions. This analysis is a stage of the study of differentiated treatment effect in groups of standard and hypofractionated regimens of radiation therapy in patients with glioblastoma. These data can be used for an in-depth subgroup analysis and serve as the basis for development of personalized approaches in treatment of neuro-oncological patients.
- 29 December 2023
- Published by Institute for Medical Radiology and Oncology of NAMS of Ukraine in Український радіологічний та онкологічний журнал
- Vol. 31 (4) , 362-377
Open AccessFactors affecting the survival of patients with glioblastoma treated with standard and hypofractionated radiation regimens
Background. Glioblastoma has the worst prognosis and is the most common primary tumor of the central nervous system (CNS) among adults. Since it is multimodal treatment that increases survival chances of patients with glioblastoma, the analysis of factors that affect survival is a necessary precondition for developing more effective therapeutic approaches for this cohort. Such analysis makes it possible to determine the subgroups of patients which demonstrate the biggest therapeutic benefit from certain types of multimodal treatment, thus leading to implementation of personalized neuro-oncological treatment. Purpose. To analyze factors affecting cancer-specific survival (CSS) of patients with glioblastoma in stratification of the cohort according to the regimen of adjuvant radiation therapy into groups of standard and hypofractionated treatment regimens. Materials and methods. The single-center non-randomized study is based on the analysis of the results of the cohort of 159 patients with primarily diagnosed glioblastoma that were treated over the period from 2014 to 2020 at the State Institution «Romodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine». According to the regimen of radiation therapy, the patients of the cohort (n=159) were stratified into two groups: standard regimen group – 49 (30.8%) patients (30 fractions, total radiation dose of 60.0 Gy) and hypofractionated regimen group – 110 (69.2%) patients (15 fractions, total radiation dose of 52.5 Gy). The survival of the patients was analyzed by the Kaplan–Meier method. The log-rank test was used for comparing Kaplan–Meier survival curves for different studied groups. For the purpose of studying impact of independent variables on the survival, we used regression analysis according to semiparametric proportional hazards model. Hazard ratio was calculated with 95% confidence intervals (CI). Results and discussion. The median CSS in the total cohort was 16.6 (95% CI 14.1–17.8 months) months in median follow-up time of 23.8 (95% CI 21.9–27.3) months. In standard regimen group, the median CSS was 15.7 (95% CI 14.1–17.8) months in median follow-up time of 24.4 (95% CI 23.1–25.3) months. In hypofractionated regimen group, the median CSS was 17.5 (95% CI 14.6–19.7) months in median follow-up time of 22.3 (95% CI 21.3 – 27.2) months. According to the logrank test (taking into consideration cautions about its use), no statistically significant difference in CSS of patients of both groups was determined р=0.07>0.05. For analysis of the impact of clinical factors (age, sex, radicality of the surgical treatment, chemotherapeutic treatment, functional status according to the Karnofsky scale) on the CSS of both groups, they were considered as the ones that may have different base hazard. Statistically significant impact of all studied covariates on the CSS was registered (p70 points, ceteris paribus. For male patients, the hazard of death is 1.7 times higher (р=0.016267; HR 1.7; 95% CI 1.1–2.5) than for female patients, ceteris paribus. Absence of chemotherapy in adjuvant treatment increases hazard of death by 2.37 times (HR 2.37; 95% CI 1.6–3.2), ceteris paribus. The hazard of death decreases, ceteris paribus, by 82% in chemotherapy with temozolomide and by 47% when the patient is younger than 60 years old (HR 0.53; 95% CI 0.4–0.8). Conclusions. This analysis is a stage of the study of differentiated treatment effect in groups of standard and hypofractionated regimens of radiation therapy in patients with glioblastoma. These data can be used for an in-depth subgroup analysis and serve as the basis for development of personalized approaches in treatment of neuro-oncological patients.
- Open Access
- 30 September 2023
- Published by Institute for Medical Radiology and Oncology of NAMS of Ukraine in Український радіологічний та онкологічний журнал
- Vol. 31 (3) , 255-270
Survival of elderly patients with glioblastoma after hypofractionated radiation therapy
Background. Glioblastoma (GB) is the most common primary brain tumor that is malignant, and its incidence increases with age. The prognosis for elderly patients with GB (GBe) is significantly worse than that of younger patients. Due to the global trend of aging population and age-related features of the GB cohort, the number of GBe patients is expected to increase. Although there is no full consensus regarding the clinical management of GBe, hypofractionated radiation therapy (RT) has become a common therapeutic option for elderly and/or poor prognosis GB patients. Purpose. To analyze the survival of patients with glioblastoma in the age group ≥60 years old after standard and hypofractionated regimens of adjuvant radiation therapy. Materials and methods. A retrospective single-center non-randomized study based on a total cohort of 53 patients (≥60 years old) with histogically verified diagnosis of GB was performed at the State Institution «Romodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine» over the period of 6 years, from 2014 to 2020. According to the RT regimen, patients were stratified into 2 groups: standard RT (SRT group) – 16 (30.2%) patients (30 fractions, 2.0 Gy per fraction, total radiation dose – 60.0 Gy) and hypofractionated RT (HRT group) – 37 (69.8%) patients (15 fractions, 3.5 Gy per fraction, total dose – 52.5 Gy). Cancer-specific survival (CSS) and progression-free survival (PFS) were analyzed in the total cohort and both groups separately. Results. With a median follow-up of 21.9 months (95% CI (confidence interval) 20.7 – 32.3), the median CSS in the total cohort was 15.0 (95% CI 13.3 – 17.3) months; the median PFS – 9.0 (95% CI 8.0 – 10.6) months. In the HRT group, the median CSS was 14.7 (95% CI 10.5 – 18.5) months; in the SRT group – 15.0 (95% CI 12.4 – 19.3) months. In the HRT group, the median PFS was 9.0 (95% CI 7.0 – 11.9) months; in the SRT group – 9.0 (95% CI 8.0 – 11.0) months. Before and after the stratification point of 15 months, the HRT and SRT groups did not differ significantly in CSS (Log-rank test p = 0.0588 and p = 0.2009, respectively). There was no significant difference in PFS between the HRT and SRT groups before and after the stratification point of 9 months (Log-rank test p = 0.0653 and p = 0.0722, respectively). Conclusions. Improving survival of GBe pts is an urgent issue, especially taking into account global trends in population aging and age-specific features of GB. The proposed hypofractionated RT regime can be considered as an optional approach in the complex treatment of GBe pts.
- 30 September 2023
- Published by Institute for Medical Radiology and Oncology of NAMS of Ukraine in Український радіологічний та онкологічний журнал
- Vol. 31 (3) , 255-270
Open AccessSurvival of elderly patients with glioblastoma after hypofractionated radiation therapy
Background. Glioblastoma (GB) is the most common primary brain tumor that is malignant, and its incidence increases with age. The prognosis for elderly patients with GB (GBe) is significantly worse than that of younger patients. Due to the global trend of aging population and age-related features of the GB cohort, the number of GBe patients is expected to increase. Although there is no full consensus regarding the clinical management of GBe, hypofractionated radiation therapy (RT) has become a common therapeutic option for elderly and/or poor prognosis GB patients. Purpose. To analyze the survival of patients with glioblastoma in the age group ≥60 years old after standard and hypofractionated regimens of adjuvant radiation therapy. Materials and methods. A retrospective single-center non-randomized study based on a total cohort of 53 patients (≥60 years old) with histogically verified diagnosis of GB was performed at the State Institution «Romodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine» over the period of 6 years, from 2014 to 2020. According to the RT regimen, patients were stratified into 2 groups: standard RT (SRT group) – 16 (30.2%) patients (30 fractions, 2.0 Gy per fraction, total radiation dose – 60.0 Gy) and hypofractionated RT (HRT group) – 37 (69.8%) patients (15 fractions, 3.5 Gy per fraction, total dose – 52.5 Gy). Cancer-specific survival (CSS) and progression-free survival (PFS) were analyzed in the total cohort and both groups separately. Results. With a median follow-up of 21.9 months (95% CI (confidence interval) 20.7 – 32.3), the median CSS in the total cohort was 15.0 (95% CI 13.3 – 17.3) months; the median PFS – 9.0 (95% CI 8.0 – 10.6) months. In the HRT group, the median CSS was 14.7 (95% CI 10.5 – 18.5) months; in the SRT group – 15.0 (95% CI 12.4 – 19.3) months. In the HRT group, the median PFS was 9.0 (95% CI 7.0 – 11.9) months; in the SRT group – 9.0 (95% CI 8.0 – 11.0) months. Before and after the stratification point of 15 months, the HRT and SRT groups did not differ significantly in CSS (Log-rank test p = 0.0588 and p = 0.2009, respectively). There was no significant difference in PFS between the HRT and SRT groups before and after the stratification point of 9 months (Log-rank test p = 0.0653 and p = 0.0722, respectively). Conclusions. Improving survival of GBe pts is an urgent issue, especially taking into account global trends in population aging and age-specific features of GB. The proposed hypofractionated RT regime can be considered as an optional approach in the complex treatment of GBe pts.
- Open Access
- 15 June 2023
- Published by Institute for Medical Radiology and Oncology of NAMS of Ukraine in Український радіологічний та онкологічний журнал
- Vol. 31 (2) , 206-229
Aspects of hypofractionation in modern radiation oncology
Background. In the modern world, the incidence of cancer diseases is rapidly increasing and is the second most common cause of death. This is preconditioned by the quantitative growth of the senior and elderly population, as well as the growth of the main risk factors for cancer, which is related to the socio-economic development of society. About half of cancer cases require radiation therapy (RT) as a component of multimodal treatment, therefore its improvement, namely the introduction of hypofractionated radiation regimens, is considered today as one of the most effective ways to increase availability of oncological care and optimize the use of health care system resources. Purpose. To find out clinical and medico-social advantages of the hypofractionated approach in radiation oncology in order to optimize the functioning of the health care system by increasing availability of treatment for cancer patients. To highlight the importance of hypofractionated RT in terms of evidence-based medicine for the most common oncological pathology and in neuro-oncology. To demonstrate the influence of the COVID-19 pandemic on the implementation of hypofractionated RT. To present our own experience of using hypofractionated radiation regimens in patients with glioblastoma (GB). Materials and methods. MEDLINE (Pubmed), EMBASE (Ovid), Web of Science (Web of Knowledge) databases were used to search for literature. The search was performed in the English-language sources with the following keywords: «Radiation», «Hypofractionation radiotherapy», «Hypofractionated radiotherapy», «Hypofractionated irradiation»; «Breast cancer»; «Prostate cancer»; «Lung cancer»; «Glioblastoma», COVID-19. Systematic reviews, meta-analyses, randomized controlled trials and retrospective clinical trials were reviewed in full. The primary sources were backreferenced to identify additional relevant studies related to hypofractionated radiation treatment regimens. The last date of the search is 05.25.2023. The authors’ own experience of the hypofractionated approach in the adjuvant radiation treatment of patients with GB is presented briefly, as a reflection of the relevance of the authors’ practical experience to the provisions of the narrative review, based on the results of a retrospective single-center non-randomized study conducted at the State Institution «Romodanov Neurosurgery Institute National Academy of Medical Sciences of Ukraine» in 2014–2020. The oncological results of 110 (69.2%) patients of the hypofractionated RT group (15 fractions, single fraction dose (SFD) 3.5 Gy, total fraction dose (TFD) 52.5 Gy) and 49 (30.8%) patients of the standard RT group (30 fractions, RVD 2.0 Gy, SVD 60.0 Gy) were compared. RT was performed with Trilogy linear accelerator (USA) (6 MeV) using the intensity-modulated radiotherapy method (IMRT). Overall survival (OS) and recurrence-free survival (RFS) in the groups were analyzed. Results and discussion. Hypofractionated approaches, which allow to significantly decrease the duration of radiation treatment, have clinical, medical and social advantages, including: increased comfort for a patient; reduction of the workload on staff and technological equipment of medical facilities; reduction of the cost of treatment. The introduction of hypofractionated RT allows to increase access to cancer care at the global level, reducing disparity in the results of treatment of cancer patients between low- and middle-income countries and the countries with high income level. Hypofractionated radiation regimens are included in the clinical guidelines of professional associations, as for the most common forms of cancer and for malignant brain tumors, and represent the standard of treatment for particular clinical cases. Our experience of using the hypofractionated radiation regimen is based on the adjuvant radiation treatment of 110 patients with GB and in terms of clinical results is a relevant concept presented in a narrative review. The analysis showed no statistical difference between the groups of standard fractionation and hypofractionated RT in OS (Logrank test p = 0.06757) and RFS (Logrank test p = 0.43374). In the hypofractionation group, with an observation time median of 22.3 months, the OS median was 16.5 (95% CI 14.1–18.8) months; median RFS was 9.0 (95% CI 8.0–10.0) months. In the standard radiation regimen group, with a median of observation time of 24.4 months, the median OS was 15.0 (95% CI 14.1–17.1) months; median RFS is 9.0 (95% CI 9.0–10.0) months. Conclusion. Development and implementation of the measures designed to optimize the use of resources of medical facilities of Ukraine is a necessary condition for maintaining high-quality care for cancer patients in the conditions of full-scale military aggression, which has been ongoing since February 24, 2022. Increased application of hypofractionated approaches in radiation oncology can be considered as a potential tool for optimization of the use of resources of the healthcare system of Ukraine and enhancing public health. Актуальність. В сучасному світі частота онкологічних захворювань стрімко зростає і є другою за поширеністю причиною смерті. Це зумовлено як кількісним зростанням населення старшого та похилого віку, так і зростанням основних факторів ризику раку, що пов’язано з соціально-економічним розвитком суспільства. Близько половини випадків онкозахворювань потребують променевої терапії (ПТ) як складової мультимодального лікування, тому її удосконалення, а саме впровадження...
- 15 June 2023
- Published by Institute for Medical Radiology and Oncology of NAMS of Ukraine in Український радіологічний та онкологічний журнал
- Vol. 31 (2) , 206-229
Open AccessAspects of hypofractionation in modern radiation oncology
Background. In the modern world, the incidence of cancer diseases is rapidly increasing and is the second most common cause of death. This is preconditioned by the quantitative growth of the senior and elderly population, as well as the growth of the main risk factors for cancer, which is related to the socio-economic development of society. About half of cancer cases require radiation therapy (RT) as a component of multimodal treatment, therefore its improvement, namely the introduction of hypofractionated radiation regimens, is considered today as one of the most effective ways to increase availability of oncological care and optimize the use of health care system resources. Purpose. To find out clinical and medico-social advantages of the hypofractionated approach in radiation oncology in order to optimize the functioning of the health care system by increasing availability of treatment for cancer patients. To highlight the importance of hypofractionated RT in terms of evidence-based medicine for the most common oncological pathology and in neuro-oncology. To demonstrate the influence of the COVID-19 pandemic on the implementation of hypofractionated RT. To present our own experience of using hypofractionated radiation regimens in patients with glioblastoma (GB). Materials and methods. MEDLINE (Pubmed), EMBASE (Ovid), Web of Science (Web of Knowledge) databases were used to search for literature. The search was performed in the English-language sources with the following keywords: «Radiation», «Hypofractionation radiotherapy», «Hypofractionated radiotherapy», «Hypofractionated irradiation»; «Breast cancer»; «Prostate cancer»; «Lung cancer»; «Glioblastoma», COVID-19. Systematic reviews, meta-analyses, randomized controlled trials and retrospective clinical trials were reviewed in full. The primary sources were backreferenced to identify additional relevant studies related to hypofractionated radiation treatment regimens. The last date of the search is 05.25.2023. The authors’ own experience of the hypofractionated approach in the adjuvant radiation treatment of patients with GB is presented briefly, as a reflection of the relevance of the authors’ practical experience to the provisions of the narrative review, based on the results of a retrospective single-center non-randomized study conducted at the State Institution «Romodanov Neurosurgery Institute National Academy of Medical Sciences of Ukraine» in 2014–2020. The oncological results of 110 (69.2%) patients of the hypofractionated RT group (15 fractions, single fraction dose (SFD) 3.5 Gy, total fraction dose (TFD) 52.5 Gy) and 49 (30.8%) patients of the standard RT group (30 fractions, RVD 2.0 Gy, SVD 60.0 Gy) were compared. RT was performed with Trilogy linear accelerator (USA) (6 MeV) using the intensity-modulated radiotherapy method (IMRT). Overall survival (OS) and recurrence-free survival (RFS) in the groups were analyzed. Results and discussion. Hypofractionated approaches, which allow to significantly decrease the duration of radiation treatment, have clinical, medical and social advantages, including: increased comfort for a patient; reduction of the workload on staff and technological equipment of medical facilities; reduction of the cost of treatment. The introduction of hypofractionated RT allows to increase access to cancer care at the global level, reducing disparity in the results of treatment of cancer patients between low- and middle-income countries and the countries with high income level. Hypofractionated radiation regimens are included in the clinical guidelines of professional associations, as for the most common forms of cancer and for malignant brain tumors, and represent the standard of treatment for particular clinical cases. Our experience of using the hypofractionated radiation regimen is based on the adjuvant radiation treatment of 110 patients with GB and in terms of clinical results is a relevant concept presented in a narrative review. The analysis showed no statistical difference between the groups of standard fractionation and hypofractionated RT in OS (Logrank test p = 0.06757) and RFS (Logrank test p = 0.43374). In the hypofractionation group, with an observation time median of 22.3 months, the OS median was 16.5 (95% CI 14.1–18.8) months; median RFS was 9.0 (95% CI 8.0–10.0) months. In the standard radiation regimen group, with a median of observation time of 24.4 months, the median OS was 15.0 (95% CI 14.1–17.1) months; median RFS is 9.0 (95% CI 9.0–10.0) months. Conclusion. Development and implementation of the measures designed to optimize the use of resources of medical facilities of Ukraine is a necessary condition for maintaining high-quality care for cancer patients in the conditions of full-scale military aggression, which has been ongoing since February 24, 2022. Increased application of hypofractionated approaches in radiation oncology can be considered as a potential tool for optimization of the use of resources of the healthcare system of Ukraine and enhancing public health. Актуальність. В сучасному світі частота онкологічних захворювань стрімко зростає і є другою за поширеністю причиною смерті. Це зумовлено як кількісним зростанням населення старшого та похилого віку, так і зростанням основних факторів ризику раку, що пов’язано з соціально-економічним розвитком суспільства. Близько половини випадків онкозахворювань потребують променевої терапії (ПТ) як складової мультимодального лікування, тому її удосконалення, а саме впровадження...
- Open Access
- 27 March 2023
- Published by Romodanov Neurosurgery Institute in Ukrainian Neurosurgical Journal
- Vol. 29 (1) , 38-47
Hypofractionated radiotherapy of patients with glioblastoma: the first experience in Ukraine and prospects view
Objective: To assess the survival of patients (pts) with newly diagnosed glioblastoma (GBM) in groups with hypofractionated regime radiotherapy, standard fractionationated regime radiotherapy and whole brain irradiation. Materials and methods: A retrospective non-randomized single-center study of 205 pts with GBM grade 4 according to the WHO classification treated in Romodanov Neurosurgery Institute named after Acad. A.P. Romodanov National Academy of Medical Science of Ukraine (2014–2020). The mean age of pts 53.8 years (95% CI 52.1 - 55.5); there were 114 men (55.6%) and 91 women (44.4%). According to the regimen radiotherapy (RT), pts were divided into 3 groups: 49 (23.9%) pts (standard RT: 2.0 Gy per fraction in 30 fractions, total dose 60.0 Gy) – group "sRT", 110 (53.7%) pts (hypofractionated RT: 3.5 Gy per fraction in 15 fractions, total dose 52, 5 Gy) - group "hRT", 46 (22.4%) pts – group "WBRT" (whole brain radiation). Differences in progression-free survival (PFS) and overall survival (OS) between the three groups were analyzed using Kaplan–Meier survival curve, log-rank test and Pearson Chi-square test. Results: The median OS is 15,0 (95% CI 14,1 – 17,1), 16,5 (95% CI 14,1 – 18,8) and 8,7 (95% CІ 7,5 – 9,5) months for sRT, hRT and WBRT, respectively. There is a significant difference in OS for sRT and hRT compared to WBRT (p=0.00000), without difference in OS between sRT and hRT (p=0.06757). The median PFS in sRT and hRT does not differ significantly: sRT – 9.0 (95% CI 9.0 - 10.0) months; hRT – 9.0 (95% CI 8.0 - 10.0) months. The median OS for WBRT is 5.1 (95% CI 4.0 - 6.0) months. There is a significant difference in PFS for sRT and hRT compared to the WBRT (p=0.00000), without difference in PFS between sRT and hRT (p=0.43374). The risk of death for WBRT compared to sRT is 2.5 times higher (HR 2.5 [95% CI, 1.45 - 4.46)) and 3.5 times higher compared to the hRT group (HR 3.5 [95% CI, 2.09-5.88)). The risk of progression for WBRT is 2.8 times higher (HR 2.78 [95% CI, 1.63-4.74)) compared to sRT, and 3.1 times higher (HR 3.12 [95% CI, 1.91-5.10)) compared to hRT. The broad implementation of hRT into clinical practice is specific to all modern radiation oncology. This trend is currently underway due to the specific positive clinical effects of hRT, which are discussed in detail in our publication. Conclusions: Our study demonstrates comparable survival outcome between sRT and hRT groups. This is an argument in favor of the feasibility of using hRT as a part of multimodal GBM treatment in terms of oncological outcomes. Further studies are needed to identify specific stratification groups of GMB patients with the greatest survival and quality of life benefits due to hRT.
- 27 March 2023
- Published by Romodanov Neurosurgery Institute in Ukrainian Neurosurgical Journal
- Vol. 29 (1) , 38-47
Open AccessHypofractionated radiotherapy of patients with glioblastoma: the first experience in Ukraine and prospects view
Objective: To assess the survival of patients (pts) with newly diagnosed glioblastoma (GBM) in groups with hypofractionated regime radiotherapy, standard fractionationated regime radiotherapy and whole brain irradiation. Materials and methods: A retrospective non-randomized single-center study of 205 pts with GBM grade 4 according to the WHO classification treated in Romodanov Neurosurgery Institute named after Acad. A.P. Romodanov National Academy of Medical Science of Ukraine (2014–2020). The mean age of pts 53.8 years (95% CI 52.1 - 55.5); there were 114 men (55.6%) and 91 women (44.4%). According to the regimen radiotherapy (RT), pts were divided into 3 groups: 49 (23.9%) pts (standard RT: 2.0 Gy per fraction in 30 fractions, total dose 60.0 Gy) – group "sRT", 110 (53.7%) pts (hypofractionated RT: 3.5 Gy per fraction in 15 fractions, total dose 52, 5 Gy) - group "hRT", 46 (22.4%) pts – group "WBRT" (whole brain radiation). Differences in progression-free survival (PFS) and overall survival (OS) between the three groups were analyzed using Kaplan–Meier survival curve, log-rank test and Pearson Chi-square test. Results: The median OS is 15,0 (95% CI 14,1 – 17,1), 16,5 (95% CI 14,1 – 18,8) and 8,7 (95% CІ 7,5 – 9,5) months for sRT, hRT and WBRT, respectively. There is a significant difference in OS for sRT and hRT compared to WBRT (p=0.00000), without difference in OS between sRT and hRT (p=0.06757). The median PFS in sRT and hRT does not differ significantly: sRT – 9.0 (95% CI 9.0 - 10.0) months; hRT – 9.0 (95% CI 8.0 - 10.0) months. The median OS for WBRT is 5.1 (95% CI 4.0 - 6.0) months. There is a significant difference in PFS for sRT and hRT compared to the WBRT (p=0.00000), without difference in PFS between sRT and hRT (p=0.43374). The risk of death for WBRT compared to sRT is 2.5 times higher (HR 2.5 [95% CI, 1.45 - 4.46)) and 3.5 times higher compared to the hRT group (HR 3.5 [95% CI, 2.09-5.88)). The risk of progression for WBRT is 2.8 times higher (HR 2.78 [95% CI, 1.63-4.74)) compared to sRT, and 3.1 times higher (HR 3.12 [95% CI, 1.91-5.10)) compared to hRT. The broad implementation of hRT into clinical practice is specific to all modern radiation oncology. This trend is currently underway due to the specific positive clinical effects of hRT, which are discussed in detail in our publication. Conclusions: Our study demonstrates comparable survival outcome between sRT and hRT groups. This is an argument in favor of the feasibility of using hRT as a part of multimodal GBM treatment in terms of oncological outcomes. Further studies are needed to identify specific stratification groups of GMB patients with the greatest survival and quality of life benefits due to hRT.
- Open Access
- 24 June 2022
- Published by Romodanov Neurosurgery Institute in Ukrainian Neurosurgical Journal
- Vol. 28 (2) , 46-53
Stages of stereotactic radiosurgery in the treatment of recurrent glioblastomas
Objective: to evaluate the effectiveness of stereotactic radiosurgery as a therapy method taking into account overall survival in patients with recurrent glioblastoma at all stages of treatment. Materials and methods. A sample of patients (66 ailments) who were treated in 2016-2021 with a molecularly confirmed diagnosis of wild-type glioblastoma was analyzed. Only patients, who, were treated in several stages and as a rule, underwent stereotaxic radiosurgery (SRS), or SRS alone after a biopsy, or SRS in case of relapse, after surgery and radiotherapy, or SRS for subsequent relapses were selected. When evaluating the results, the following were taken into account: 1) age at the diagnosis, 2) volume of surgical resection, 3) use of radiation therapy, 4) use of adjuvant chemotherapy after SRS and response evluation criteria in solid tumors. Overall survival (OS) was assessed after diagnosis and at the time of SRS. Results. Patients received SRS at an average 10 months after initial diagnosis. Median duration of follow-up was 8 months after SRS and 12 months after diagnosis, median OS for all patients was nine months (1 to 42 months) after SRS and 20 months (4 to 64 months) respectively. The median survival after SRS was 9 months (p=0.008; χ2=7.008). The median OS for younger patients (50 years) was 14.8 months (p=0.04; χ2=3.870). The median overall survival rate was 32.2 months in patients who received SRS 10 months after the diagnosis was made, and 16 months in those who received SRS earlier than 10 months (p=0.004, χ2=8.145). Radiosurgical doses ≥15 Gy were correlated with a mean survival rate of nine months and seven months in patients treated at doses 2=6.756). In patients who received adjuvant therapy with bevacizumab and/or chemotherapy after SRS, the median OS was 12 months, in patients who did not receive additional therapy after SRS, it was 7 months (p=0.04, χ2=4.19). Conclusions. Stereotactic radiosurgery promotes the effectiveness of glioblastoma treatment due to the possibility of carrying out this method at various stages of treatment. The overall survival of our patients depended on the period of SRS after diagnosis, patient age, radiation dose, and adjuvant chemotherapy.
- 24 June 2022
- Published by Romodanov Neurosurgery Institute in Ukrainian Neurosurgical Journal
- Vol. 28 (2) , 46-53
Open AccessStages of stereotactic radiosurgery in the treatment of recurrent glioblastomas
Objective: to evaluate the effectiveness of stereotactic radiosurgery as a therapy method taking into account overall survival in patients with recurrent glioblastoma at all stages of treatment. Materials and methods. A sample of patients (66 ailments) who were treated in 2016-2021 with a molecularly confirmed diagnosis of wild-type glioblastoma was analyzed. Only patients, who, were treated in several stages and as a rule, underwent stereotaxic radiosurgery (SRS), or SRS alone after a biopsy, or SRS in case of relapse, after surgery and radiotherapy, or SRS for subsequent relapses were selected. When evaluating the results, the following were taken into account: 1) age at the diagnosis, 2) volume of surgical resection, 3) use of radiation therapy, 4) use of adjuvant chemotherapy after SRS and response evluation criteria in solid tumors. Overall survival (OS) was assessed after diagnosis and at the time of SRS. Results. Patients received SRS at an average 10 months after initial diagnosis. Median duration of follow-up was 8 months after SRS and 12 months after diagnosis, median OS for all patients was nine months (1 to 42 months) after SRS and 20 months (4 to 64 months) respectively. The median survival after SRS was 9 months (p=0.008; χ2=7.008). The median OS for younger patients (50 years) was 14.8 months (p=0.04; χ2=3.870). The median overall survival rate was 32.2 months in patients who received SRS 10 months after the diagnosis was made, and 16 months in those who received SRS earlier than 10 months (p=0.004, χ2=8.145). Radiosurgical doses ≥15 Gy were correlated with a mean survival rate of nine months and seven months in patients treated at doses 2=6.756). In patients who received adjuvant therapy with bevacizumab and/or chemotherapy after SRS, the median OS was 12 months, in patients who did not receive additional therapy after SRS, it was 7 months (p=0.04, χ2=4.19). Conclusions. Stereotactic radiosurgery promotes the effectiveness of glioblastoma treatment due to the possibility of carrying out this method at various stages of treatment. The overall survival of our patients depended on the period of SRS after diagnosis, patient age, radiation dose, and adjuvant chemotherapy.
- Open Access
- 27 March 2022
- Published by Bogomolets National Medical University in Ukrainian Scientific Medical Youth Journal
- Vol. 128 (1) , 57-73
Survival after stereotactic radiosurgery of recurrent glioblastomas in patients with radical resection of primary tumor
гліобластома (ГБ) – це агресивна пухлина, що характеризується високим рівнем рецидивування та призводить до смерті більшості хворих через 15–18 місяців після встановлення діагнозу. Факторами, що асоціюються з більш тривалою виживаністю хворих на ГБ, є вік до 50 років, кращий функціональний статус та радикальна резекція первинної пухлини. Оптимальне лікування при рецидиві або прогресуванні ГБ до цього часу не визначено та залишається складною проблемою. Стереотаксична радіохірургія (СРХ) є методом прецизійного високотехнологічного опромінення, що розглядається сьогодні як терапевтична опція ефективного впливу на рецидивні злоякісні гліоми. Метою даного ретроспективного дослідження був аналіз виживаності після СРХ рецидивної ГБ в когорті 59 хворих, яким було проведено радикальну резекцію первинної пухлини. Досліджувана когорта складалась з 59 хворих (28 / 47,5% жінок та 31 / 52,5% чоловіків); середній вік в загальній групі склав 51 рік (інтервал 24 – 81). СРХ проводилось на лінійному прискорювачі «Trilogy» (США) (6 MeV) в період з 2014 р. по 2020 р. в Державній установі «Інститут нейрохірургії ім. акад. А.П. Ромоданова НАМН України». В усіх випадках діагноз ГБ 4 ступеню за класифікацією ВООЗ був підтверджений патоморфологічно після резекції первинної пухлини. Всім 59 хворим було проведено максимальне безпечне видалення первинної пухлини в радикальному об’ємі: в переважній кількості спостережень (54 / 91,5%) – по перифокальній зоні; в 5 / 8,5% випадках – субтотально. В усіх 59 випадках хворим було проведено ад’ювантне променеве лікування після видалення первинної пухлини (сумарна вогнищева доза (СВД) 60 Гр, 30 фракцій), яке в 33 випадках було поєднане з алкілюючою ХТ (темозоломід 75 мг/м2). У 31 / 52,5 % хворого після завершення конкомітантної ХТ продовжилось ХТ лікування (темозоломід 150-200 мг/ м2). У більшості спостережень (51 / 86,4 %) РГБ було діагностовано за сукупністю клініко-радіологічних ознак; у 8 / 13,6 % хворих – патоморфологічно, після повторного хірургічного втручання. Кінцевими точками дослідження були загальна виживаність (ЗВ), безрецидивна (безпрогресивна) виживаність (БРВ) та виживаність після настання рецидиву (ВПР). Вивчався вплив на виживаність наступних кількісних та категоріальних факторів: стать, вік, функціональний статус, поєднання ад’ювантної ПТ з алкілюючою ХТ, хірургічне видалення РГБ, тип рецидивування ГБ, дозове навантаження за всі курси опромінення сумарно (за біологічно-ефективною дозою (BED11)) та при СРХ, кількість фракцій СРХ, об’єм мішені СРХ, термін безрецидивного періоду/виживаності (БРВ). Вплив на виживаність такого фактору як БРВ досліджувався шляхом розподілення когорти на три незалежні групи в залежності від тривалості безрецидивного періоду: група I – БРВ < 10 місяців; група II – БРВ від 10 до 20 місяців; група III – БРВ > 20 місяців. Виживаність хворих була проаналізована методом Каплана-Майера (КМ). Логарифмічний ранговий тест (для порівняння КМ кривих виживаності для різних досліджуваних груп) використовували для дослідження виживаності за бінарними предикторами. Порівняння впливу декількох категоріальних факторів на виживаність здійснювалось за допомогою χ2-тесту (Pearson Chi-square test). Для дослідження впливу на виживаність кількісних коваріат використовували регресійний аналіз за моделлю пропорційних ризиків...
- 27 March 2022
- Published by Bogomolets National Medical University in Ukrainian Scientific Medical Youth Journal
- Vol. 128 (1) , 57-73
Open AccessSurvival after stereotactic radiosurgery of recurrent glioblastomas in patients with radical resection of primary tumor
гліобластома (ГБ) – це агресивна пухлина, що характеризується високим рівнем рецидивування та призводить до смерті більшості хворих через 15–18 місяців після встановлення діагнозу. Факторами, що асоціюються з більш тривалою виживаністю хворих на ГБ, є вік до 50 років, кращий функціональний статус та радикальна резекція первинної пухлини. Оптимальне лікування при рецидиві або прогресуванні ГБ до цього часу не визначено та залишається складною проблемою. Стереотаксична радіохірургія (СРХ) є методом прецизійного високотехнологічного опромінення, що розглядається сьогодні як терапевтична опція ефективного впливу на рецидивні злоякісні гліоми. Метою даного ретроспективного дослідження був аналіз виживаності після СРХ рецидивної ГБ в когорті 59 хворих, яким було проведено радикальну резекцію первинної пухлини. Досліджувана когорта складалась з 59 хворих (28 / 47,5% жінок та 31 / 52,5% чоловіків); середній вік в загальній групі склав 51 рік (інтервал 24 – 81). СРХ проводилось на лінійному прискорювачі «Trilogy» (США) (6 MeV) в період з 2014 р. по 2020 р. в Державній установі «Інститут нейрохірургії ім. акад. А.П. Ромоданова НАМН України». В усіх випадках діагноз ГБ 4 ступеню за класифікацією ВООЗ був підтверджений патоморфологічно після резекції первинної пухлини. Всім 59 хворим було проведено максимальне безпечне видалення первинної пухлини в радикальному об’ємі: в переважній кількості спостережень (54 / 91,5%) – по перифокальній зоні; в 5 / 8,5% випадках – субтотально. В усіх 59 випадках хворим було проведено ад’ювантне променеве лікування після видалення первинної пухлини (сумарна вогнищева доза (СВД) 60 Гр, 30 фракцій), яке в 33 випадках було поєднане з алкілюючою ХТ (темозоломід 75 мг/м2). У 31 / 52,5 % хворого після завершення конкомітантної ХТ продовжилось ХТ лікування (темозоломід 150-200 мг/ м2). У більшості спостережень (51 / 86,4 %) РГБ було діагностовано за сукупністю клініко-радіологічних ознак; у 8 / 13,6 % хворих – патоморфологічно, після повторного хірургічного втручання. Кінцевими точками дослідження були загальна виживаність (ЗВ), безрецидивна (безпрогресивна) виживаність (БРВ) та виживаність після настання рецидиву (ВПР). Вивчався вплив на виживаність наступних кількісних та категоріальних факторів: стать, вік, функціональний статус, поєднання ад’ювантної ПТ з алкілюючою ХТ, хірургічне видалення РГБ, тип рецидивування ГБ, дозове навантаження за всі курси опромінення сумарно (за біологічно-ефективною дозою (BED11)) та при СРХ, кількість фракцій СРХ, об’єм мішені СРХ, термін безрецидивного періоду/виживаності (БРВ). Вплив на виживаність такого фактору як БРВ досліджувався шляхом розподілення когорти на три незалежні групи в залежності від тривалості безрецидивного періоду: група I – БРВ < 10 місяців; група II – БРВ від 10 до 20 місяців; група III – БРВ > 20 місяців. Виживаність хворих була проаналізована методом Каплана-Майера (КМ). Логарифмічний ранговий тест (для порівняння КМ кривих виживаності для різних досліджуваних груп) використовували для дослідження виживаності за бінарними предикторами. Порівняння впливу декількох категоріальних факторів на виживаність здійснювалось за допомогою χ2-тесту (Pearson Chi-square test). Для дослідження впливу на виживаність кількісних коваріат використовували регресійний аналіз за моделлю пропорційних ризиків...
- Open Access
- 20 March 2021
- Published by Romodanov Neurosurgery Institute in Ukrainian Neurosurgical Journal
- Vol. 27 (1) , 34-43
Current state of antiangiogenic therapy in neuro-oncology and own experience of its use in the radiosurgical treatment of recurrent glioblastoma
Objective: to study the effect of antiangiogenic therapy on the quality of life and the level of headache in patients with recurrent glioblastoma who underwent radiosurgical treatment. Materials and methods. A prospective randomized single-center study carried out at the Romodanov Neurosurgery Institute of National Academy of Medical Sciences of Ukraine in 2019-2020 involving 45 patients with GB with clinical and radiological signs of disease progression and local tumor recurrence. In this regard, patients underwent radiosurgical treatment. In the main group (BEV+) 21 patients after stereotactic radiosurgery (SRS) underwent antiangiogenic therapy with Bevacizumab (BEV). In the control group (BEV–), 24 patients did not receive antiangiogenic therapy after SRS. SRS with the use of a linear accelerator «Trilogy» (6 MeV) using intensity-modulated radiotherapy (IMRT). BEV was administered intravenously, once every 3 weeks at a dose of 10 mg / kg body weight. Antiangiogenic therapy was performed under the condition of preserved liver and kidney function, values of full blood count and blood biochemistry within normal range. Global health status and headache levels were calculated according to EORTC QLQ-C30 v. 3.0 and QLQ-BN20 before and six weeks after radiosurgery in the main and control groups. Results. There was no a statistically significant difference between the studied groups of patients’ in quality of life (p = 0.707372) and in headache level (p = 0.846660) before the SRS. Six weeks after SRS, patients in the main group had a statistically significantly higher quality of life (p = 0.000015) and a lower level of headache than patients in the control group (p = 0.000035). During the observation period in patients of both groups there were no adverse events of III-IV degree of toxicity, in particular specific complications of antiangiogenic therapy (hypertension, bleeding, thromboembolism, leukopenia, proteinuria, gastrointestinal disorders, etc.). Conclusions. Antiangiogenic therapy statistically significantly improves the quality of life and reduces the level of headache in patients who underwent radiosurgical treatment for glioblastoma recurrence.
- 20 March 2021
- Published by Romodanov Neurosurgery Institute in Ukrainian Neurosurgical Journal
- Vol. 27 (1) , 34-43
Open AccessCurrent state of antiangiogenic therapy in neuro-oncology and own experience of its use in the radiosurgical treatment of recurrent glioblastoma
Objective: to study the effect of antiangiogenic therapy on the quality of life and the level of headache in patients with recurrent glioblastoma who underwent radiosurgical treatment. Materials and methods. A prospective randomized single-center study carried out at the Romodanov Neurosurgery Institute of National Academy of Medical Sciences of Ukraine in 2019-2020 involving 45 patients with GB with clinical and radiological signs of disease progression and local tumor recurrence. In this regard, patients underwent radiosurgical treatment. In the main group (BEV+) 21 patients after stereotactic radiosurgery (SRS) underwent antiangiogenic therapy with Bevacizumab (BEV). In the control group (BEV–), 24 patients did not receive antiangiogenic therapy after SRS. SRS with the use of a linear accelerator «Trilogy» (6 MeV) using intensity-modulated radiotherapy (IMRT). BEV was administered intravenously, once every 3 weeks at a dose of 10 mg / kg body weight. Antiangiogenic therapy was performed under the condition of preserved liver and kidney function, values of full blood count and blood biochemistry within normal range. Global health status and headache levels were calculated according to EORTC QLQ-C30 v. 3.0 and QLQ-BN20 before and six weeks after radiosurgery in the main and control groups. Results. There was no a statistically significant difference between the studied groups of patients’ in quality of life (p = 0.707372) and in headache level (p = 0.846660) before the SRS. Six weeks after SRS, patients in the main group had a statistically significantly higher quality of life (p = 0.000015) and a lower level of headache than patients in the control group (p = 0.000035). During the observation period in patients of both groups there were no adverse events of III-IV degree of toxicity, in particular specific complications of antiangiogenic therapy (hypertension, bleeding, thromboembolism, leukopenia, proteinuria, gastrointestinal disorders, etc.). Conclusions. Antiangiogenic therapy statistically significantly improves the quality of life and reduces the level of headache in patients who underwent radiosurgical treatment for glioblastoma recurrence.
- Open Access
- 17 December 2020
- Published by Institute for Medical Radiology and Oncology of NAMS of Ukraine in Український радіологічний та онкологічний журнал
- Vol. 28 (4) , 353-363
Features of immune status in patients with metastatic and glial brain tumors at the preparatory stage of radiotherapy
Background. Studies carried out in recent decades have shown that immune cells are essential participants in the cancer process as well as cancerrelated inflammation. Focus has been increased on understanding the way how immune cells affect a tumor at different stages of the disease: early neoplastic transformation, clinically detected tumors, metastatic spread, and at surgery and radiotherapy stages. Purpose – assessing the status of the immune system in patients with brain tumors before radiation therapy and radiosurgery and comparing the features of immunity in metastatic and glial brain tumors. Materials and methods. The study presents the immunogram findings of 61 patients. Out of those: 18 patients with primary glial tumors and 23 patients with secondary metastatic tumors to the brain. The outcomes of 20 conditionally healthy non-cancer patients are presented as a control group. The age of patients is 24–75. All patients were histologically diagnosed with the tumor. Surgery was performed 1.0–3.0 years before the examination. Assessment of the immune system in patients with brain tumors was performed taking into account the cellular, humoral and phagocytic component of innate immunity. When assessing cellular immunity, the relative and absolute count of major lymphocyte subpopulations, such as CD3+ – general T-lymphocytes, CD4+ – T-lymphocytes-helpers, CD8+ – cytotoxic lymphocytes, CD16+ – natural killer lymphocytes, CD19+-B-lymphocytes, were calculated. Determining the humoral parameters included an assessment of quantitative values of IgG, IgM and IgA. Quantitative assessment of the phagocytic component of innate immunity included phagocytic activity of neutrophils (i. e. NBT test (Nitroblue Tetrazolium test), inducing (Zymosanum) and spontaneous neutrophil myeloperoxidase activity). Results. When comparing the immune parameters of the number of T- and B-subpopulations of lymphocytes in patients with primary malignant brain tumors and secondary metastatic tumors, no statistically significant difference has been detected between these params. Glioblastomas show higher levels of СD4+- and CD8+-lymphocytes in comparison with other tumour groups as well as higher levels of IgG and IgA than in other tumors, while IgM concentration is almost at the same level in three groups of patients. There is a tendency for reducing IgG and IgM level in the blood of patients with metastatic tumors. Both groups of cancer patients under study show inhibition of myeloperoxidase activity of neutrophils in the setting of maintaining the function of NBT cell activity. Conclusions. According to the findings obtained via studying immunological indicators of brain tumors, both metastatic and primary malignant glial ones, there are partial changes in various immune system components such as cellular, humoral and phagocytic activity. However, no statistically significant difference was detected between immune status indicators, that substantiates the need for further study of this issue. At the stage of preparation for radiation therapy, no significant changes in the immune system of the patients with brain tumors, that would make such treatment impossible and be consiered as one of contraindications, are observed.
- 17 December 2020
- Published by Institute for Medical Radiology and Oncology of NAMS of Ukraine in Український радіологічний та онкологічний журнал
- Vol. 28 (4) , 353-363
Open AccessFeatures of immune status in patients with metastatic and glial brain tumors at the preparatory stage of radiotherapy
Background. Studies carried out in recent decades have shown that immune cells are essential participants in the cancer process as well as cancerrelated inflammation. Focus has been increased on understanding the way how immune cells affect a tumor at different stages of the disease: early neoplastic transformation, clinically detected tumors, metastatic spread, and at surgery and radiotherapy stages. Purpose – assessing the status of the immune system in patients with brain tumors before radiation therapy and radiosurgery and comparing the features of immunity in metastatic and glial brain tumors. Materials and methods. The study presents the immunogram findings of 61 patients. Out of those: 18 patients with primary glial tumors and 23 patients with secondary metastatic tumors to the brain. The outcomes of 20 conditionally healthy non-cancer patients are presented as a control group. The age of patients is 24–75. All patients were histologically diagnosed with the tumor. Surgery was performed 1.0–3.0 years before the examination. Assessment of the immune system in patients with brain tumors was performed taking into account the cellular, humoral and phagocytic component of innate immunity. When assessing cellular immunity, the relative and absolute count of major lymphocyte subpopulations, such as CD3+ – general T-lymphocytes, CD4+ – T-lymphocytes-helpers, CD8+ – cytotoxic lymphocytes, CD16+ – natural killer lymphocytes, CD19+-B-lymphocytes, were calculated. Determining the humoral parameters included an assessment of quantitative values of IgG, IgM and IgA. Quantitative assessment of the phagocytic component of innate immunity included phagocytic activity of neutrophils (i. e. NBT test (Nitroblue Tetrazolium test), inducing (Zymosanum) and spontaneous neutrophil myeloperoxidase activity). Results. When comparing the immune parameters of the number of T- and B-subpopulations of lymphocytes in patients with primary malignant brain tumors and secondary metastatic tumors, no statistically significant difference has been detected between these params. Glioblastomas show higher levels of СD4+- and CD8+-lymphocytes in comparison with other tumour groups as well as higher levels of IgG and IgA than in other tumors, while IgM concentration is almost at the same level in three groups of patients. There is a tendency for reducing IgG and IgM level in the blood of patients with metastatic tumors. Both groups of cancer patients under study show inhibition of myeloperoxidase activity of neutrophils in the setting of maintaining the function of NBT cell activity. Conclusions. According to the findings obtained via studying immunological indicators of brain tumors, both metastatic and primary malignant glial ones, there are partial changes in various immune system components such as cellular, humoral and phagocytic activity. However, no statistically significant difference was detected between immune status indicators, that substantiates the need for further study of this issue. At the stage of preparation for radiation therapy, no significant changes in the immune system of the patients with brain tumors, that would make such treatment impossible and be consiered as one of contraindications, are observed.